A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in Patients With Chronic Heart Failure (NYHA Class II - IV). The Study is Also Known as Aliskiren Trial of Minimizing OutcomeS in Patients With HEart Failure (ATMOSPHERE).

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in Patients With Chronic Heart Failure (NYHA Class II - IV). The Study is Also Known as Aliskiren Trial of Minimizing OutcomeS in Patients With HEart Failure (ATMOSPHERE).

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Aliskiren (Primary) ; Enalapril
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms ASPIRE-HIGHER; ATMOSPHERE
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 14 Nov 2017 Results of pooled data from two trial (PARADIGM-HF and ATMOSPHERE), were published in the Journal of the American College of Cardiology.
    • 01 Oct 2017 Results (n=14,737) from NCT00853658 and NCT01035255 studies published in the Circulation: Heart Failure.
    • 25 Sep 2017 Results of subgroup analysis published in the European Journal of Heart Failure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top